Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.2

Margin Of Safety %

30

Put/Call OI Ratio

1.3

EPS Next Q Diff

-0.71

EPS Last/This Y

1.98

EPS This/Next Y

0.47

Price

50.05

Target Price

61

Analyst Recom

1.75

Performance Q

4.62

Relative Volume

0.5

Beta

0.47

Ticker: SNY




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-06SNY49.721.031.3470604
2025-10-07SNY49.21.040.1271757
2025-10-08SNY48.791.082.9271264
2025-10-09SNY48.821.090.6272151
2025-10-10SNY48.091.080.9774085
2025-10-13SNY48.811.092.0374262
2025-10-14SNY49.221.090.5074431
2025-10-15SNY48.941.090.1274481
2025-10-16SNY50.021.050.0976165
2025-10-17SNY50.621.030.2576919
2025-10-20SNY49.731.251.9353030
2025-10-21SNY49.691.294.8654270
2025-10-22SNY50.021.320.2555062
2025-10-23SNY49.521.300.6055411
2025-10-24SNY51.621.290.4356346
2025-10-27SNY51.391.271.7756463
2025-10-28SNY51.061.273.9056578
2025-10-29SNY50.691.271.9056711
2025-10-30SNY50.931.293.6558050
2025-10-31SNY50.571.301.6658648
2025-11-03SNY50.051.301.2658749
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-06SNY49.722.64301.84.61
2025-10-07SNY49.202.64019.54.59
2025-10-08SNY48.802.64055.54.59
2025-10-09SNY48.822.64097.94.59
2025-10-10SNY48.092.63909.14.59
2025-10-13SNY48.812.64283.64.59
2025-10-14SNY49.212.64389.84.59
2025-10-15SNY48.942.64174.04.59
2025-10-16SNY50.012.64287.34.56
2025-10-17SNY50.622.64221.44.56
2025-10-20SNY49.732.63983.24.56
2025-10-21SNY49.672.63946.44.56
2025-10-22SNY49.992.64069.44.56
2025-10-23SNY49.512.63887.34.56
2025-10-24SNY51.602.64428.24.56
2025-10-27SNY51.372.63752.24.56
2025-10-28SNY51.0617.03720.34.50
2025-10-29SNY50.7017.03711.44.50
2025-10-30SNY50.9417.03898.14.54
2025-10-31SNY50.5817.03711.74.54
2025-11-03SNY50.0517.03635.14.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-06SNY0-4.040.20
2025-10-07SNY0-4.040.20
2025-10-08SNY0-4.040.20
2025-10-09SNY0-4.040.20
2025-10-10SNY0-4.040.17
2025-10-13SNY0-4.090.17
2025-10-14SNY0-4.090.17
2025-10-16SNY0-4.090.17
2025-10-17SNY0-4.090.17
2025-10-20SNY0-4.090.17
2025-10-21SNY0-4.090.17
2025-10-22SNY0-4.090.17
2025-10-23SNY0-4.090.17
2025-10-24SNY0-4.090.17
2025-10-27SNY0-4.410.20
2025-10-28SNY0-4.410.20
2025-10-29SNY0.00-4.410.20
2025-10-30SNY0.00-4.410.20
2025-10-31SNY0.00-4.410.20
2025-11-03SNY0.00-4.950.20
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.7

Avg. EPS Est. Current Quarter

0.8

Avg. EPS Est. Next Quarter

0.99

Insider Transactions

Institutional Transactions

-4.95

Beta

0.47

Average Sales Estimate Current Quarter

11006

Average Sales Estimate Next Quarter

10120

Fair Value

65.21

Quality Score

94

Growth Score

87

Sentiment Score

72

Actual DrawDown %

16.7

Max Drawdown 5-Year %

-33.5

Target Price

61

P/E

12.5

Forward P/E

10.22

PEG

1.02

P/S

2.82

P/B

1.48

P/Free Cash Flow

11.29

EPS

4.01

Average EPS Est. Cur. Y​

4.54

EPS Next Y. (Est.)

5.02

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

22.98

Relative Volume

0.5

Return on Equity vs Sector %

-19.4

Return on Equity vs Industry %

-30.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

3635.1
Sanofi
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 82878
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health – Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
stock quote shares SNY – Sanofi Stock Price stock today
news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025
marketwatch SNY – Sanofi yahoo finance google finance
stock history SNY – Sanofi invest stock market
stock prices SNY premarket after hours
ticker SNY fair value insiders trading